A San Francisco based biotechnology company announced the initiation of a program to develop a coronavirus vaccine candidate targeting the novel coronavirus 2019-nCoV.
This development effort is based on the oral vaccine platform, VAAST.
‘An oral vaccine administered using a room temperature-stable tablet could be of logistical and critical benefit during major public health vaccination campaigns,’ says Vaxart, Inc.
In a press release published on January 31, 2020, Sean Tucker, Ph.D., chief scientific officer of Vaxart, said, “The results of our recently published influenza challenge study demonstrated that our oral tablet vaccine primarily protects through mucosal immunity, a potential key factor when targeting mucosal pathogens, such as this new coronavirus.”
Vaxart said it plans to generate vaccine candidates based on the published genome of the novel coronavirus (2019-nCoV) and evaluate them in preclinical models for their ability to generate both mucosal and systemic immune responses.
Of particular interest will be the mucosal immune responses, as coronavirus is primarily an infection of the respiratory tract.
To date, Vaxart has conducted multiple clinical trials…
This News From Feed news.google title “Oral Vaccine Enters 2019-nCoV Development Competition – PrecisionVaccinations”
geico insurance,instant auto insurance quote,get auto insurance online,purchase auto insurance online,auto insurance quotes online,farmers insurance,farm insurance,a car insurance